HOXA9

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDS

Retrieved on: 
Monday, December 12, 2022

In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).

Key Points: 
  • In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).
  • This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS patients.
  • This study shows that Cellworks personalized therapy biosimulation, which was based on each patients genomic aberrations, reveals a high spectrum of DS among patients with MDS.
  • The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology.

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

Retrieved on: 
Friday, August 26, 2022

We previously reported the ability of BMF-219 to modulate MYC expression and exhibit high potency against Double HIT Lymphoma (DHL) DLBCL (Diffuse Large B Cell Lymphoma) preclinical models.

Key Points: 
  • We previously reported the ability of BMF-219 to modulate MYC expression and exhibit high potency against Double HIT Lymphoma (DHL) DLBCL (Diffuse Large B Cell Lymphoma) preclinical models.
  • Additionally, we provide mechanistic evidence for direct inhibition of menin protein, in cell line models representing MM, DHL and DEL.
  • Collectively, our data demonstrate the novel and robust anti-tumor activity of BMF-219 in HGBCL and MM preclinical models that represent categories of high unmet need.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022

The AACR Annual Meeting will be held from April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • The AACR Annual Meeting will be held from April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In preclinical models, BMF-219 demonstrated near complete tumor growth inhibition in both MYC-dependent and pan-KRAS mutant cancers.
  • These mutations are broadly manifested in numerous tumor types and are generally considered categories of very high unmet need.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Spleen Tyrosine Kinase Inhibitors Pipeline Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022

The "Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape.
  • Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells.
  • The companies which have their Spleen tyrosine kinase inhibitors drug candidates in the most advanced stage, i.e.

Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia

Retrieved on: 
Monday, December 6, 2021

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in the registrational Phase 3 AGILITY clinical trial of entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK), in combination with standard of care anthracycline and cytarabine (7+3) chemotherapy. This trial is the first in acute myeloid leukemia (AML) to use measurable residual disease (MRD) as the primary endpoint and has the potential to support accelerated approval of entospletinib by the U.S. Food and Drug Administration (FDA) as a treatment for patients newly diagnosed with NPM1-mutated AML who are fit for intensive induction.

Key Points: 
  • Entospletinib is Kronos Bios lead product candidate, and the company expects to share data from the trial in the second half of 2023.
  • This trial will test the hypothesis, based on robust preclinical and Phase 2 clinical data, that NPM1 mutation leads to dependency on SYK signaling.
  • In the trial, patients will be randomized 1:1 to receive either entospletinib or placebo in combination with standard induction and consolidation chemotherapy.
  • Kronos Bio is developing entospletinib for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).

Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)

Retrieved on: 
Tuesday, July 27, 2021

SAN MATEO, Calif. and CAMBRIDGE, Mass., July 27, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for lanraplenib (LANRA), allowing the company to proceed with a Phase 1/2 clinical trial of LANRA in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia (AML) in combination with gilteritinib. Kronos Bio expects to initiate the trial in the fourth quarter of this year. The company is developing LANRA as a next-generation spleen tyrosine kinase (SYK) inhibitor, with improved pharmacokinetic (PK) and pharmacologic properties compared with entospletinib (ENTO), the company’s lead program. ENTO will be evaluated in combination with standard chemotherapy in a planned Phase 3 clinical trial in patients newly diagnosed with NPM1-mutated AML.

Key Points: 
  • Previously, LANRA demonstrated an acceptable safety profile in clinical trials of more than 250 healthy volunteers and patients with autoimmune diseases.
  • Kronos Bio is developing ENTO for the treatment of patients who are newly diagnosed with NPM1-mutated acute myeloid leukemia (AML) and eligible for intensive induction chemotherapy.
  • Results of a Phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with induction chemotherapy in newly diagnosed patients with acute myeloid leukemia.
  • Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: response and predictive significance of HOXA9 and MEIS1 expression.

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

Retrieved on: 
Thursday, March 4, 2021

Even with current therapies, about half of patients with newly diagnosed NPM1-mutated AML will die from the disease within five years.

Key Points: 
  • Even with current therapies, about half of patients with newly diagnosed NPM1-mutated AML will die from the disease within five years.
  • Kronos Bios lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • Results of a Phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with induction chemotherapy in newly diagnosed patients with acute myeloid leukemia.
  • Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: response and predictive significance of HOXA9 and MEIS1 expression.